Compare LGO & TIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LGO | TIL |
|---|---|---|
| Founded | 1988 | 2018 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 87.5M | 74.7M |
| IPO Year | 2007 | 2021 |
| Metric | LGO | TIL |
|---|---|---|
| Price | $1.23 | $7.13 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 4 |
| Target Price | $3.30 | ★ $125.00 |
| AVG Volume (30 Days) | ★ 561.5K | 255.4K |
| Earning Date | 11-12-2025 | 03-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $111,884,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $53.91 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.85 | $5.67 |
| 52 Week High | $2.70 | $42.79 |
| Indicator | LGO | TIL |
|---|---|---|
| Relative Strength Index (RSI) | 63.23 | 31.20 |
| Support Level | $1.05 | $6.91 |
| Resistance Level | $1.24 | $7.42 |
| Average True Range (ATR) | 0.09 | 0.69 |
| MACD | 0.03 | -0.30 |
| Stochastic Oscillator | 90.81 | 20.30 |
Largo Inc is committed to the production and supply of high-quality vanadium products. The company is also focused on the advancement of renewable energy storage solutions through Largo Clean Energy and its vanadium redox flow battery technology. The Company is engaged in the mining, exploration, and development of mineral properties, predominantly in Brazil, through which it produces and supplies vanadium products VPURE Flake, VPURE+ Flake, and VPURE+ Powder. The company has operating segments: sales & trading, mine properties, which generates key revenue, corporate, exploration and evaluation properties, Clean Energy, and Largo Physical Vanadium.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.